The ALDH6A1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line, carrying a targeted disruption of the ALDH6A1 gene. This gene encodes methylmalonate-semialdehyde dehydrogenase (MMSDH), an enzyme central to the catabolism of valine and pyrimidines. The polyclonal knockout population is generated by CRISPR/Cas9-mediated gene disruption, providing a heterogeneous pool of cells with loss-of-function mutations that enable robust investigation of ALDH6A1-dependent metabolic processes.
The A-549 cell line was originally established from a 58-year-old Caucasian male with lung carcinoma and serves as a widely accepted model for studying respiratory epithelial biology and lung adenocarcinoma. These cells exhibit an epithelial morphology and are extensively employed in drug metabolism and cancer research, making them a valuable host for examining the metabolic vulnerabilities of non-small cell lung cancer. Their well-characterized background supports reproducible and physiologically relevant experimental systems.
At the molecular level, ALDH6A1 catalyzes the irreversible oxidative decarboxylation of malonate semialdehyde and methylmalonate semialdehyde to acetyl-CoA and propionyl-CoA, using NAD? and CoA as cofactors. This reaction bridges valine, thymine, and uracil degradation with the TCA cycle. ALDH6A1 expression is regulated by transcription factors including PPARA, PPARG, and PPARGC1A, and is responsive to insulin signaling. Downstream products acetyl-CoA and propionyl-CoA serve as precursors for TCA cycle intermediates and cofactors for histone acetylation, linking metabolic flux to epigenetic control. Pathway components such as BCAT2, BCKDHA, ACADSB, ECHS1, HIBCH, ACSS3, DPYD, DPYS, and UPB1 mediate the upstream catabolic steps.
In A-549 lung adenocarcinoma cells, disruption of ALDH6A1 ablates a key metabolic node, potentially altering acetyl-CoA pools and impacting cellular proliferation, energy metabolism, and histone acetylation dynamics. This knockout model provides a unique platform to dissect how mitochondrial substrate-level oxidation supports cancer cell fitness and epigenetic regulation. Given the high metabolic demands of tumors, examining ALDH6A1 loss may reveal context-specific liabilities that can be targeted in lung cancer therapy.
The ALDH6A1 Knockout A-549 Polyclonal Cells are designed for a broad spectrum of applications, including metabolic flux analysis with labeled valine or thymine, quantification of acetyl-CoA and propionyl-CoA levels, and methylmalonic acid measurement by HPLC. They facilitate studies on drug metabolism, methylmalonate semialdehyde dehydrogenase deficiency, and the interplay between metabolism and epigenetic modifications. Representative assays include Western blotting, RT-qPCR, viability and proliferation assays, histone acetylation profiling, migration and invasion assays, and drug sensitivity screening. For further technical information, please contact Ascent Research.
